Literature DB >> 14656347

Remodelling of the upper airways in allergic rhinitis: is it a feature of the disease?

R J Salib1, P H Howarth.   

Abstract

The traditional viewpoint that inflammation, owing to a genetic T-helper type 2 (Th2)-directed imbalance, is the cause of allergic rhinitis has meant that the potential coexistence of other genetic defects and the relevance of any airway remodelling changes to disease pathogenesis and persistence have received scant attention, and as such remain controversial areas. This is particularly so in view of the limited published work in this field, which has so far reported markedly conflicting findings. This review endeavours to outline what is known about the nature of the remodelling response within the upper airway in allergic rhinitis, in addition to highlighting specific areas where further research is warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656347     DOI: 10.1111/j.1365-2222.2003.01828.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  17 in total

1.  Anti-allergic effect of the naturally-occurring conjugated linolenic acid isomer, jacaric acid, on the activated human mast cell line-1.

Authors:  Wai Nam Liu; Kwok Nam Leung
Journal:  Biomed Rep       Date:  2015-09-24

2.  Remodeling in Allergic Rhinitis. Adding New Data to an Old Debate.

Authors:  Jonathan Corren; Alkis Togias
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

Review 3.  Rodent models of allergic rhinitis: relevance to human pathophysiology.

Authors:  James G Wagner; Jack R Harkema
Journal:  Curr Allergy Asthma Rep       Date:  2007-05       Impact factor: 4.806

Review 4.  Allergy and the lung.

Authors:  G Passalacqua; G Ciprandi
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

5.  Intraperitoneal mesenchymal stem cell administration ameliorates allergic rhinitis in the murine model.

Authors:  Sakine Işık; Meral Karaman; Aysun Adan; Müge Kıray; Hüsnü Alper Bağrıyanık; Şule Çağlayan Sözmen; İlknur Kozanoğlu; Özkan Karaman; Yusuf Baran; Nevin Uzuner
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-07-05       Impact factor: 2.503

6.  Expression and Roles of MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2 in Allergic Nasal Mucosa.

Authors:  Sachiko Mori; Ruby Pawankar; Chika Ozu; Manabu Nonaka; Toshiaki Yagi; Kimihiro Okubo
Journal:  Allergy Asthma Immunol Res       Date:  2012-06-12       Impact factor: 5.764

7.  Prolonged Treatment with Inhaled Corticosteroids does not Normalize High Activity of Matrix Metalloproteinase-9 in Exhaled Breath Condensates of Children with Asthma.

Authors:  Katarzyna Grzela; Wioletta Zagorska; Alicja Krejner; Malgorzata Litwiniuk; Anna Zawadzka-Krajewska; Aleksandra Banaszkiewicz; Marek Kulus; Tomasz Grzela
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-02-04       Impact factor: 4.291

Review 8.  EAACI position paper on occupational rhinitis.

Authors:  Gianna Moscato; Olivier Vandenplas; Roy Gerth Van Wijk; Jean-Luc Malo; Luca Perfetti; Santiago Quirce; Jolanta Walusiak; Roberto Castano; Gianni Pala; Denyse Gautrin; Hans De Groot; Ilenia Folletti; Mona Rita Yacoub; Andrea Siracusa
Journal:  Respir Res       Date:  2009-03-03

9.  Inhibition of angiogenic factor production from murine mast cells by an antiallergic agent (epinastine hydrochloride) in vitro.

Authors:  K Asano; A Furuta; K Kanai; S Sakaue; H Suzaki; T Hisamitsu
Journal:  Mediators Inflamm       Date:  2008       Impact factor: 4.711

10.  Suppression of matrix metalloproteinase production in nasal fibroblasts by tranilast, an antiallergic agent, in vitro.

Authors:  Toshiyuki Shimizu; Kenichi Kanai; Kazuhito Asano; Tadashi Hisamitsu; Harumi Suzaki
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.